Key Drivers
- Strong liquidity
- Ongoing cash burn
- Negative equity
AIAI Summary
VOR is now a funded but highly binary telitacicept bet: its ~$514.5M liquidity runway supports operations through the pivotal first-half 2027 MG readout, but investment upside depends on proving China-derived efficacy can differentiate against entrenched global autoimmune competitors—making clinical validation, not near-term financing, the key decision point.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Ongoing cash burn
- •Negative equity
VOR has strong near-term liquidity but remains high-risk due to rapid cash burn, no revenue, persistent losses, and negative equity.
Price Behavior
Key Price Behavior Insights:
- •Accelerating decline
- •Support test
- •Lower highs
VOR fell 7% over the last month and remains bearish below $23.13, with a break under $21.40 signaling further downside while reclaiming $23.10–$23.25 would improve momentum.
Decline accelerated after the $25.10 peak
Sentiment & News
Key News Insights:
- •Phase 3 enrolled
- •Ocular MG expansion
- •Strong liquidity
Vor Bio completed UPSTREAM MG enrollment, expanded telitacicept into ocular MG, and remains funded for key 2027 readouts amid strong competition.
The updates support Vor Bio's development momentum, though clinical execution and competitive risks remain key catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings